SAR443820 + itraconazole

SAR443820 + itraconazole is a combination regimen of **SAR443820** (a novel investigational drug) and **itraconazole** (a triazole antifungal agent). Itraconazole is well-established as a small molecule antifungal that inhibits **fungal 14α-demethylase**, interfering with ergosterol synthesis and disrupting fungal cell membrane integrity[1][3]. The mechanism of action for SAR443820 is not established in the data provided, but it is likely used for investigational purposes in conjunction with itraconazole, possibly for infection management or drug-drug interaction studies. Itraconazole is approved for various fungal infections, such as blastomycosis, histoplasmosis, aspergillosis, and is commonly used orally[1][3][4][5]. Clinical data specific to the combination are not available, suggesting SAR443820 itself is not yet an approved pharmaceutical ingredient.